• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

    11/13/24 12:41:46 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $QTRX alert in real time by email
    SC 13G/A 1 tm2428231d2_sc13ga.htm SC 13G/A

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d–2.
    (Amendment No. 1)*

     

    Quanterix Corporation

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    74766Q101

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 74766Q101
     
      1.

    Names of Reporting Persons

    Portolan Capital Management, LLC

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4

    Citizenship or Place of Organization

    Delaware

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

     

    2,520,686

     
    6. Shared Voting Power
     
    7.

    Sole Dispositive Power

     

    2,520,686

     
    8.

    Shared Dispositive Power

     

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,520,686

     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11.

    Percent of Class Represented by Amount in Row (9)

    6.57%

     
      12. Type of Reporting Person (See Instructions)
    IA

     

     

     

     

    CUSIP No.  74766Q101
     
      1.

    Names of Reporting Persons

    George McCabe

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3. SEC Use Only
     
      4

    Citizenship or Place of Organization

    USA

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5.

    Sole Voting Power

     

    2,520,686

     
    6.

    Shared Voting Power

     
    7.

    Sole Dispositive Power

     

    2,520,686

     
    8.

    Shared Dispositive Power

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,520,686

     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11.

    Percent of Class Represented by Amount in Row (9)

    6.57%

     
      12.

    Type of Reporting Person (See Instructions)

    IN

     

     

     2 

     

     

    Item 1.
      (a)

    Name of Issuer

    Quanterix Corporation

      (b)

    900 Middlesex Turnpike

    Billerica, Massachusetts 01821

     
    Item 2.
      (a)

    Name of Person Filing

    This statement is being filed with respect to the shares of class A common stock (“Common Stock”) of the Issuer beneficially owned (1) directly by Portolan Capital Management, LLC, a registered investment adviser, in its capacity as investment manager for various clients, and (2) indirectly by George McCabe, the Manager of Portolan Capital Management, LLC. Portolan Capital Management, LLC and Mr. McCabe are sometimes individually referred to herein as a “Reporting Person” and collectively as the “Reporting Persons.”

      (b)

    Address of Principal Business Office or, if none, Residence

    Portolan Capital Management, LLC and George McCabe

    2 International Place, FL 26, Boston, MA 02110

      (c)

    Citizenship

    Portolan Capital Management, LLC – DE

    Mr. McCabe – USA

      (d)

    Title of Class of Securities

    Common Stock

      (e)

    CUSIP Number

    74766Q101

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     3 

     

     

    Item 4. Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    Reference is hereby made to Items 5-9 and 11 of pages 1 - 2 of this Schedule, which Items are incorporated by reference herein.

     
    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨.

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
    Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of Quanterix Corporation.  No one person's interest in the Common Stock of Quanterix Corporation is more than five percent of the total outstanding Common Stock.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    Not applicable
     
    Item 8. Identification and Classification of Members of the Group
    Not applicable
     
    Item 9. Notice of Dissolution of Group
    Not applicable

     

     4 

     

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      November 13, 2024
      Date
       
     
    Portolan Capital Management, LLC
     
      By:  /s/ George McCabe
        George McCabe, Manager
       
      /s/ George McCabe
      George McCabe

     

      ATTENTION  
         
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     5 

     

    Get the next $QTRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTRX

    DatePrice TargetRatingAnalyst
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    2/1/2024$30.00Sector Outperform
    Scotiabank
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    8/8/2023$30.00Market Perform → Outperform
    SVB Securities
    5/23/2023$13.00 → $27.00Neutral → Buy
    Goldman
    8/15/2022$40.00 → $12.00Buy → Hold
    Canaccord Genuity
    8/9/2022$38.00 → $18.00Outperform → Market Perform
    Cowen
    8/9/2022$35.00 → $15.00Outperform → Mkt Perform
    SVB Leerink
    More analyst ratings

    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Meadows Benjamin bought $9,695 worth of shares (3,500 units at $2.77) (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/12/26 5:32:14 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Sriram Vandana bought $19,878 worth of shares (4,150 units at $4.79), increasing direct ownership by 5% to 87,200 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    9/17/25 10:24:11 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/13/25 4:39:15 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quanterix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00

    8/11/25 9:55:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on Quanterix with a new price target

    Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00

    2/1/24 6:32:54 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously

    9/25/23 9:03:48 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the "Inducement Grant") was made to Jason Faessler in connection with the commencement of his employment as the Chief Financial officer and Treasurer of the Company. The Inducement Grant consisted of 141,820 restricted stock units ("RSUs") representing 141,820 shares of Quanterix common stock. The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the Company or one of its subsidiaries through the vesting dates. The Ind

    7/16/26 4:05:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

    Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood Quanterix Corporation (NASDAQ:QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment. The announce

    7/14/26 4:29:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the "Inducement Grants") were made to three employees in connection with the commencement of their employment. The Inducement Grants consisted of 336,804 restricted stock units ("RSUs") representing 336,804 shares of Quanterix common stock. The RSUs vest in four equal installments on the first four anniversaries of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. T

    6/16/26 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    SEC Filings

    View All

    Quanterix Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Quanterix Corp (0001503274) (Filer)

    6/10/26 4:16:58 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Quanterix Corp (0001503274) (Filer)

    6/9/26 8:06:33 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Quanterix Corp (0001503274) (Filer)

    5/26/26 5:25:36 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 36,068 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    7/16/26 5:33:41 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Chief Financial Officer Faessler Jason F.

    4 - Quanterix Corp (0001503274) (Issuer)

    7/16/26 5:31:47 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Mendel Scott converted options into 8,073 shares, increasing direct ownership by 51% to 24,056 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    7/9/26 5:20:29 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Financials

    Live finance-specific insights

    View All

    Quanterix Releases Financial Results for the First Quarter of 2026

    Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition," said Everett Cunningham, President & CEO of Quanterix. "As part of this process, we are focusing our

    5/6/26 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. In conjunction with this announcement, the Company will host a conference call on May 6, 2026, at 4:30 PM ET. The dial-in number for USA & Canada

    4/24/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation Announces Date of 2026 Annual Meeting

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the "Company"), today announced that the Company's 2026 annual meeting of shareholders (the "Annual Meeting") will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote at the Annual Meeting. Additional information regarding the Annual Meeting will be provided in the Company's proxy statement. Because the date of the Annual Meeting has been advanced by more than thirty (30) days from the anniversary

    3/27/26 4:00:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's strategic growth plans in the coming years. "We are thrilled to welcome Jason to the Quanterix leadership team," said Everett Cunningham, Chief Executive Officer of Quanterix. "His extensive track record within life science organization

    6/9/26 8:03:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

    Strategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante

    6/4/26 8:02:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

    SC 13G/A - Quanterix Corp (0001503274) (Subject)

    11/13/24 12:41:46 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Quanterix Corporation

    SC 13G - Quanterix Corp (0001503274) (Subject)

    6/27/24 2:46:59 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

    SC 13G/A - Quanterix Corp (0001503274) (Subject)

    2/14/24 4:57:53 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials